Lyell Immunopharma, Inc. – NASDAQ:LYEL
Lyell Immunopharma stock price today
$10.83
+10.18
+1566.15%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Lyell Immunopharma stock price monthly change
-61.99%
month
Lyell Immunopharma stock price quarterly change
-61.99%
quarter
Lyell Immunopharma stock price yearly change
-69.19%
year
Lyell Immunopharma key metrics
Market Cap | 175.85M |
Enterprise value | N/A |
P/E | -3.51 |
EV/Sales | -1.64 |
EV/EBITDA | 0.37 |
Price/Sales | 0.01 |
Price/Book | N/A |
PEG ratio | -0.05 |
EPS | -0.90 |
Revenue | 68K |
EBITDA | -217.74M |
Income | -228.34M |
Revenue Q/Q | -95.38% |
Revenue Y/Y | -99.81% |
Profit margin | -480.75% |
Oper. margin | -474.03% |
Gross margin | 0% |
EBIT margin | -474.03% |
EBITDA margin | -320211.76% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLyell Immunopharma stock price history
Lyell Immunopharma stock forecast
Lyell Immunopharma financial statements
Average Price Target
$1
Potential downside: -90.76%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 27K | -63.89M | -236629.63% |
|---|---|---|---|
| Sep 2023 | 25K | -50.85M | -203412% |
| Dec 2023 | 13K | -52.93M | -407153.85% |
| Mar 2024 | 3K | -60.66M | -2022233.33% |
| 2023-11-07 | -0.27 | -0.2 |
|---|---|---|
| 2024-02-28 | -0.21 | -0.2 |
| 2024-05-06 | -0.2 | -0.24 |
| Jun 2023 | 835354000 | 98.49M | 11.79% |
|---|---|---|---|
| Sep 2023 | 794989000 | 97.41M | 12.25% |
| Dec 2023 | 750029000 | 95.07M | 12.68% |
| Mar 2024 | 694220000 | 91.06M | 13.12% |
| Jun 2023 | -39.16M | 152.91M | 1.19M |
|---|---|---|---|
| Sep 2023 | -37.68M | 99.67M | -143K |
| Dec 2023 | -40.63M | -100.69M | 759K |
| Mar 2024 | -42.01M | 21.99M | 27K |
Lyell Immunopharma alternative data
| Aug 2023 | 274 |
|---|---|
| Sep 2023 | 274 |
| Oct 2023 | 274 |
| Nov 2023 | 274 |
| Dec 2023 | 274 |
| Jan 2024 | 274 |
| Feb 2024 | 274 |
| Apr 2024 | 224 |
| May 2024 | 224 |
| Jun 2024 | 224 |
| Jul 2024 | 224 |
Lyell Immunopharma other data
16.80%
-30.16%
of LYEL is owned by hedge funds
59
-33
41.50M
-75.10M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2022 | 0 | 11100 |
| Aug 2023 | 0 | 58020 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | KLAUSNER RICHARD director | Common Stock | 58,020 | $2.28 | $132,286 | ||
Sale | KLAUSNER RICHARD director | Common Stock | 11,100 | $6.4 | $71,040 | ||
Option | BISHOP HANS EDGAR director | Option (right to buy) | 145,380 | $0.1 | $14,538 | ||
Option | BISHOP HANS EDGAR director | Common Stock | 145,380 | $0.1 | $14,538 | ||
Option | BISHOP HANS EDGAR director | Option (right to buy) | 993,428 | $0.1 | $99,343 | ||
Option | BISHOP HANS EDGAR director | Common Stock | 993,428 | $0.1 | $99,343 | ||
Purchase | FRIEDMAN CATHY director | Common Stock | 17,648 | $17 | $300,016 |
| Insider | Compensation |
|---|---|
| Dr. Richard D. Klausner M.D. (1952) Executive Chairman | $1,430,000 |
Ms. Elizabeth Homans (1966) Chief Executive Officer & Director | $1,140,000 |
| Ms. Heather D. Turner (1973) Chief Gen. Counsel & Sec. | $917,080 |
Mr. Stephen J. Hill (1970) Chief Operating Officer | $722,580 |
-
What's the price of Lyell Immunopharma stock today?
One share of Lyell Immunopharma stock can currently be purchased for approximately $10.83.
-
When is Lyell Immunopharma's next earnings date?
Unfortunately, Lyell Immunopharma's (LYEL) next earnings date is currently unknown.
-
Does Lyell Immunopharma pay dividends?
No, Lyell Immunopharma does not pay dividends.
-
How much money does Lyell Immunopharma make?
Lyell Immunopharma has a market capitalization of 175.85M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 99.85% to 130K US dollars. Lyell Immunopharma made a loss 234.63M US dollars in net income (profit) last year or -$0.24 on an earnings per share basis.
-
What is Lyell Immunopharma's stock symbol?
Lyell Immunopharma, Inc. is traded on the NASDAQ under the ticker symbol "LYEL".
-
What is Lyell Immunopharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Lyell Immunopharma?
Shares of Lyell Immunopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Lyell Immunopharma's key executives?
Lyell Immunopharma's management team includes the following people:
- Dr. Richard D. Klausner M.D. Executive Chairman(age: 73, pay: $1,430,000)
- Ms. Elizabeth Homans Chief Executive Officer & Director(age: 59, pay: $1,140,000)
- Ms. Heather D. Turner Chief Gen. Counsel & Sec.(age: 52, pay: $917,080)
- Mr. Stephen J. Hill Chief Operating Officer(age: 55, pay: $722,580)
-
How many employees does Lyell Immunopharma have?
As Jul 2024, Lyell Immunopharma employs 224 workers.
-
When Lyell Immunopharma went public?
Lyell Immunopharma, Inc. is publicly traded company for more then 4 years since IPO on 17 Jun 2021.
-
What is Lyell Immunopharma's official website?
The official website for Lyell Immunopharma is lyell.com.
-
Where are Lyell Immunopharma's headquarters?
Lyell Immunopharma is headquartered at 201 Haskins Way, South San Francisco, CA.
-
How can i contact Lyell Immunopharma?
Lyell Immunopharma's mailing address is 201 Haskins Way, South San Francisco, CA and company can be reached via phone at +65 06950677.
-
What is Lyell Immunopharma stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Lyell Immunopharma in the last 12 months, the avarage price target is $1. The average price target represents a -90.76% change from the last price of $10.83.
Lyell Immunopharma company profile:
Lyell Immunopharma, Inc.
lyell.comExchange:
NASDAQ
Full time employees:
224
Industry:
Biotechnology
Sector:
Healthcare
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
201 Haskins Way
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001806952
ISIN: US55083R1041
CUSIP: 55083R104
